Page values for "Lemborexant"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`
brand	`String`	Dayvigo
structure	`File`
classes	List of `String`, delimiter: `,`	Dual orexin receptor antagonist (DORA)
mechanism	`String`	Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance.
uses	`String`	Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019)
starting_dose	`String`	5 mg PO at bedtime; may increase to 10 mg if inadequate
preparations	`String`	5 mg, 10 mg tablets
fda_max	`String`	10 mg/d
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	~30 min
duration	`String`	~7-8 hours
halflife	`String`	~17-19 hours (longer than daridorexant)
bioavailability	`String`	~44%
pregnancy	`String`	Limited data; avoid
legal	`String`	Rx, Schedule IV (US)